BTIG upgrades NeoGenomics stock with $28.00 price target

BTIG has upgraded NeoGenomics from Neutral to Buy, setting a price target of $28.00. Additionally, Needham issued a Buy rating for the company with a target of $22.00, up from a previous $19.00.

NeoGenomics reported a second-quarter revenue of $201.66 million for 2026, an 8.02 percent increase from the first quarter. The company's net income improved from a loss of $17.11 million in Q1 to a profit of $2.24 million in Q2. Analysts are projecting third-quarter revenue of approximately $206.70 million and earnings per share of $0.0555.

The company is currently listed on the Nasdaq with a market capitalization of $2.2 billion.